Biogen | Frais De Vente Et D'Administration



Selling And Administration Expenses Changement Date
AbbVie USD 3.29B 562M 2025-03
Acadia Pharmaceuticals USD 130.08M 3.21M 2024-12
ALKERMES USD 146.99M 3.39M 2024-12
Amgen USD 1.88B 253M 2024-12
Bayer EUR 4.34B 610M 2024-12
Biogen USD 677.3M 99.6M 2024-12
BioMarin Pharmaceutical USD 256.77M 46.81M 2024-12
Bristol-Myers Squibb USD 1.58B 521M 2025-03
Eli Lilly USD 2.42B 324.7M 2024-12
Gilead Sciences USD 1.26B 603M 2025-03
Incyte USD 325.69M 1.02M 2025-03
Merck USD 2.53B 319M 2025-03
Moderna USD 351M 70M 2024-12
Neurocrine Biosciences USD 287.8M 53.5M 2024-12
Novartis USD 3.5B 368M 2024-12
Pfizer USD 3.01B 1.27B 2025-03
PTC Therapeutics USD 84.68M 11.23M 2024-12
Regeneron Pharmaceuticals USD 633M 159.2M 2025-03
Sanofi EUR 2.22B 980M 2025-03
Sanofi EUR 1.24B 1.44B 2024-12
Sarepta Therapeutics USD 163.87M 35.67M 2024-12
Teva Pharmaceutical Industries USD 952M 28M 2024-12
Ultragenyx Pharmaceutical USD 82.49M 2.14M 2024-12
United Therapeutics USD 162.5M 8.4M 2024-12
Vertex Pharmaceuticals USD 377.6M 5.8M 2024-12



Biogen Frais De Vente Et D'Administration - Les valeurs actuelles, des données historiques, des prévisions, des statistiques, des tableaux et le calendrier économique - Apr 2025.